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Background/Objective: Microwave-based devices target sweat glands through energy delivery at the
dermalesubcutaneous interface. These devices have been approved by the Food and Drug Administra-
tion as a noninvasive treatment for axillary hyperhidrosis. Treatment for osmidrosis has only been re-
ported in one preliminary study. This study aimed to investigate the efﬁcacy, safety, and histological
changes of the microwave-based devices in treating axillary osmidrosis.
Methods: We conducted a prospective study in a tertiary referral center in Taiwan. Patients with axillary
osmidrosis were recruited and received two consecutive treatment sessions with a 3-month interval.
Skin biopsy was obtained to evaluate histological changes. The efﬁcacy was determined by odor
reduction using a patient reported 10-point odor scale. Responders were deﬁned as participants with a
reduction of at least 3 points of the Odor-10 score at their 90-day follow-up visit.
Results: Seven patients were enrolled. Mean reduction of odor was 61.8%. Six patients met the primary
endpoint of odor reduction. Skin biopsy specimens reveled 93% reduction of apocrine glands. Histo-
pathological changes include dermal ﬁbrosis, necrosis of sweat glands, and subcutaneous fat necrosis.
Transient swelling, bruise, numbness, lumps, and hypotrichosis were possible side effects. No patient
reported disabling side effects.
Conclusion: Microwave-based devices are noninvasive and a potential alternative therapeutic modality
for axillary osmidrosis treatment.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Axillary osmidrosis refers to an offensive and unpleasant body
odor from the axillary area. It is a very distressing issue impairing
an individual's psychosocial well-being. Secretions from the
apocrine glands of the axillae are responsible for the malodor.
Thus, several surgical techniques have been developed to remove
the glands, but the results and complication rates vary.1e3
Microwave-based devices, approved by the United States Food
and Drug Administration, have been developed to treat axillaryhave no ﬁnancial or nonﬁ-
tter or materials discussed in
logy, Chang Gung Memorial
n.
).
cal Association. Published by Elsevhyperhidrosis by selectively heating the interface between the
skin and underlying fat of the axilla.4 However, treatment of
axillary osmidrosis using this technique has only been reported in
one preliminary study.5
The objectives of this study were to investigate the efﬁcacy,
safety, and histological changes of microwave-based devices in
treating axillary osmidrosis.
Materials and methods
Patients
Seven adults with axillary osmidrosis (aged 22e53 years, 2 men
and 5women) were enrolled in a single-group unblinded study in a
tertiary referral medical center in Taiwan. All patients were rated 3
or 4 on the hyperhidrosis disease severity scale (HDSS) and at leastier Taiwan LLC. All rights reserved.
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scopic thoracic sympathectomy, liposuction, or other surgeries for
axillary osmidrosis or hyperhidrosis. They had no botulinum toxin
injection within 1 year, and had not used any topical treatment
within 14 days prior to treatment.
The study was approved by Chang Gung Memorial Hospital's
institutional review board (103-4012C4), and informed consent
was obtained prior to any study procedures.Odor and sweat assessments
All participants were asked to record their own perception of their
underarm odor using a 10-point scale (Odor-10), where 1 stands for
completely no odor and 10 for severe odor.
The method of assessing the level of axillary sweat was patient-
reported HDSS score. Table 1 provides the deﬁnition of the four
scores respectively.Treatment
Baseline evaluation including past medical history, physical ex-
amination, and sweat and odor self-assessment (HDSS and Odor-
10) were performed on each patient. An incisional skin biopsy
was taken from the left central axilla. The incision was 1.5-cm in
length and depth to the deep subcutis. Treatment sessions began 1
month after the skin biopsy to avoid wound dehiscence during
microwave treatment.
After being marked with a treatment template, the axillary area
was anesthetized with 1% lidocaine with 1:100,000 epinephrine.
Both axillary areas were fully treated by miraDry system (Miramar
Labs, Santa Clara, CA, USA), which is a microwave-based device
with integrated vacuum and cooling included. It allows different
energy settings within a small range. Energy level 3 (the middle
energy setting), which is the most commonly used setting in pre-
vious reports,4 was used for the ﬁrst treatment session. The second
sessionwas carried out 3months after the ﬁrst session. Energy level
was increased to level 5 because there were no apparent side ef-
fects after the ﬁrst treatment. The second session also covered the
entire bilateral axilla region.
After completion of all sessions, all patients attended follow-up
visits 30 days and 90 days after their last session. An additional skin
biopsy was taken from a location 1 cm away from the previous
biopsy site in the ipsilateral axilla to avoid scar tissue at their 30-
day follow-up visits.Study efﬁcacy and patient satisfaction measurement
Efﬁcacy of odor reduction was measured using the Odor-10 score.
For the study's primary endpoint, responders were deﬁned as a
reduction of at least 3 points on the Odor-10 score at their 90-day
follow-up visit. In addition, the HDSS score was used as a mea-
surement of sweat reduction. Responders were deﬁned asTable 1 Hyperhidrosis disease severity scale deﬁnition.
Score How would you rate the severity of your hyperhidrosis?
1 My underarm sweating is never noticeable and never interferes
with my daily activities
2 My underarm sweating is tolerable but sometimes interferes
with my daily activities
3 My underarm sweating is barely tolerable and frequently interferes
with my daily activities
4 My underarm sweating is intolerable and always interferes
with my daily activitiesparticipants reporting a HDSS score of 1 or 2 at their 90-day follow-
up visits.
All participants were asked about their satisfaction regarding
the whole procedure at the 90-day follow-up visit. Patient satis-
faction score was ranked on a scale of 1 to 5 (1 ¼ very dissatisﬁed,
2 ¼ somewhat dissatisﬁed 3 ¼ no comment, 4 ¼ very satisﬁed, and
5 ¼ absolutely satisﬁed).
Histological evaluation
The skin biopsy specimens were stained with hematoxylin and
eosin. All slides were reviewed by a dermatopathologist. Histo-
logical changes after the treatments were evaluated in terms of
the reduction of apocrine glands, changes in hair follicles, nerves,
and subcutaneous fat. Immunohistochemistry staining with
CAM5.2 (BD Biosciences, Franklin Lakes, New Jersey, USA), which
reacts with low molecular weight cytokeratin, was used to high-
light apocrine sweat glands. All the immunohistochemistry slides
were photographed and stored digitally. The total area of the tis-
sue (TAT) and the area of the tissue containing apocrine sweat
glands (AAG) were measured using computerized image process-
ing software (Adobe Photoshop, San Jose, CA, USA) and subjected
to statistical analysis.6 Probability of error < 0.05 was set as the
cut-point for level of signiﬁcance.
Safety assessments
Postoperative pain was recorded using numeric pain rating scale
from D0 to D6 after each treatment session. If there was discrep-
ancy in pain between two sides of axilla, the higher pain score was
recorded.
During each visit, patients were asked about adverse events. The
degree towhich the events were associatedwith the procedurewas
judged by the investigators. All events were monitored until they
were adequately resolved.
Results
Demography
Demographic information and baseline sweat assessment values
for all participants are shown in Table 2. All patients completed
study visits up to 90 days of follow-up. Every patient underwent
two procedure sessions and was skin biopsied twice.
Efﬁcacy and patient satisfaction
The efﬁcacy of odor and sweat reduction is shown in Table 2 and
Figure 1. Six out of seven (85.7%) patients met the primary
endpoint of odor reduction. The mean percentage of reduction in
odor-10 scale was 76.4% and 61.8%, at 30-day and 90-day visits
respectively. As for sweat reduction, six of seven (85.7%) patientsTable 2 Demographic characteristics and the results of sweat reduction.
Patient Age/Sex BMI
(kg/m2)
Baseline
Odor-10
Baseline
HDSS Score
HDSS Score
Day 30
HDSS Score
Day 90
1 27/M 23.0 10 3 2 1
2 31/F 17.0 8 4 2 3
3 25/F 22.4 8 4 3 2
4 22/F 21.2 6 3 1 1
5 35/M 21.5 5 3 1 1
6 53/F 24.4 9 3 1 1
7 32/F 18.0 9 3 3 1
BMI ¼ body mass index; HDSS ¼ hyperhidrosis disease severity scale.
Figure 1 Results of odor reduction with mean Odor-10 scale ± 1 standard deviation.
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had recurrent axillary odor and hyperhidrosis at their 90-day visit.
Four out of seven participants were very satisﬁed, two partici-
pants were satisﬁed, and only Patient 3 was somewhat dissatisﬁed
with the procedure. Overall, 85.7% of participants were satisﬁed
with the procedure.
Histological studies
Microscopic features of each postoperative specimen were recor-
ded in terms of necrosis of sweat glands, ﬁbrosis of deep dermis,
hemorrhage, hair follicle changes, fat necrosis, and nerve changes,
as shown in Table 3. The amount of eccrine and apocrine glands
decreased tremendously after treatment in all patients, as shown in
Figure 2. Moreover, necrosis of both eccrine and apocrine glands,
lymphocytic inﬁltrates with giant cells around the sweat glands,
ﬁbrosis of deep dermis, as well as subcutaneous fat necrosis were
found on high-power microscopy. The epidermis and upper dermis
remained intact (Figure 3). Hair follicles were surrounded by in-
ﬂammatory cells with dyskeratotic cells in the follicular epithelium.
Perifollicular ﬁbrosis and formation of keratin cysts all indicated
damage to hair follicles (Figure 4AeC). Nerve injury was found in
one specimen (Figure 4D).Table 3 Microscopic features after the treatment of each patient with clinical correlatio
Patient Hyalinization and necrosis
of sweat glands
Fibrosis Fat necrosis Microscopic
hemorrhage
Clinic
1 þ þ þ þ 
2 þ þ þ  
3 þ þ þ þ 
4 þ þ  þ 
5 þ þ þ þ 
6 þ þ þ  
7 þ þ þ  
a Clinical ﬁndings at 30-day follow-up visit.Immunohistochemically, apocrine glands react strongly to
CAM5.2 with heavy staining of the nucleus and cytoplasmwhereas
eccrine glands showed only little reactivity (Figure 5). The results of
apocrine sweat glands reduction are shown in Table 4. Mean
reduction in the area of apocrine sweat glands was 9.61 mm2 (95%
conﬁdence interval, 6.35e12.87 mm2) and 93% (95% conﬁdence
interval, 86.3e99.7%) in percentage. There were signiﬁcant differ-
ences between pre- and postoperative AAG and AAG/TAT ratio
(p ¼ 0.001 and p < 0.001, respectively), which represented a sub-
stantial decrease of apocrine glands.
Adverse events and safety
Postoperative painwas recorded using numeric pain scale fromDay
0 to Day 6, as shown in Figure 6. Pain score dropped dramatically
and all patients reported only mild pain 3 days after the ﬁrst
treatment. However, after the second session in which energy level
5 was used, the pain was greater and lasted longer in all patients.
Although all patients had to take diclofenac to relieve pain on the
treatment day, all reported no disabling pain interfering with ac-
tivities of daily living.
Other common adverse events included local erythema, bruise,
local swelling, numbness, andhypotrichosis (Figure 7). Erythema andn.
al bruise Microscopic hair
follicle damage
Hypotrichosis Microscopic nerve
injury
Numbnessa
þ þ  
   
 þ e þ
   
þ þ þ þ
þ   þ
   þ
Figure 2 Histopathologic ﬁndings of four out of seven patients showing reduction of sweat glands. Histology: (A, C, E, G) before treatment and (B, D, F, H) after treatment in Patients
6, 7, 2, and 5, respectively (hematoxylin and eosin, 20).
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out of seven had numbness that diminished in 1e3 months. Local
swellingmostly went away in 1e2weeks, but therewere some small
lumps remaining in all patients. Those lumps resolved gradually but
could be still be palpated in ﬁve patients at 90-day follow-up visit.Three patients reported hypotrichosis and decelerated axillary hair
growth rate, which existed up to their 90-day follow-up visit.
In summary, no severe and debilitating adverse effects were
observed. All patients showed good tolerance during all treatment
and follow-up visits.
Figure 3 (A) Fibrosis of the deep dermis [hematoxylin and eosin (H&E), 100]. (B) Hyalinization and necrosis of sweat glands (H&E, 400). (C) Fat necrosis at superﬁcial subcutis
(H&E, 400).
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There have been many reports showing good efﬁcacy in sweat
reduction using microwave-based devices. Hong et al7 demon-
strated that 90.3% patients had HDSS score of 1 or 2 at the 12-Figure 4 Damage to the hair follicles and nerves. (A) Dyskeratotic cells within the follicular e
keratin cysts. (C) Fibrosis around the hair follicle (D) Nerve injury surrounded by inﬂammamonth follow-up visit. Glaser et al8 conducted a randomized
blinded sham-controlled trial and there was a signiﬁcant differ-
ence regarding sweat reduction rate between the active treatment
group (89%) and the sham group (54%). There is only one pre-
liminary report evaluating the efﬁcacy of microwave-basedpithelium surrounded by inﬂammatory cells (arrow). (B) Degenerated hair follicles with
tory cells (arrowheads; hematoxylin and eosin, 200).
Figure 5 Immunohistochemistry staining using CAM5.2 to highlight apocrine sweat glands: (A, C, E, G) were from Patients 6, 7, 2, and 5, respectively, preoperatively, and (B, D, F, H)
were from Patients 6, 7, 2, and 5, respectively, postoperatively. Note that only Patient 2 had residual sweat glands (F).
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ﬁcacy (93.8%).5 Our study further demonstrates good efﬁcacy for
axillary hyperhidrosis and osmidrosis. At the visits 30 days and 90
days after treatment series, 100% and 85.7%, respectively, of
patients had achieved the primary end point of odor reduction.
The mean reduction in odor-10 scale was 61.8% at 90-day follow-
up visit.The safety proﬁle of the procedure showed low risk for all pa-
tients. Local swelling, erythema and pain were expected but last
only about 1 week. The degree of pain seemed to be related to the
energy level used during the treatment, since the second treatment
sessionwith higher energy level caused more pain. Ice packing and
some anti-inﬂammatories could ameliorate thesemild discomforts.
Some side effects such as numbness and local lumps might last
Table 4 Results of reduction in apocrine glands.
Patient TAT (mm2) AAG (mm2) AAG/TAT
Preop Postop Preop Postop Preop Postop
1 28.19 22.59 7.60 0.17 0.27 0.01
2 29.86 27.83 9.46 2.41 0.32 0.09
3 34.42 41.15 20.08 1.68 0.58 0.04
4 20.01 19.27 4.80 0.35 0.24 0.02
5 27.77 29.63 9.82 0.00 0.35 0.00
6 34.88 20.85 9.97 0.07 0.29 0.00
7 34.33 36.18 10.24 0.00 0.30 0.00
p* 0.65 0.001 <0.001
* Unpaired t test was used for the variable TAT and paired t test for AAG and AAG/
TAT.
AAG ¼ area of tissue containing apocrine glands; postop ¼ postoperative data;
preop ¼ preoperative data; TAT ¼ total area of the tissue.
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were nerve injuries microscopically, all patients with numbness
recovered within 1e3 months, suggesting that nerve injuries were
temporary and reversible. Hypotrichosis lasted longer, as there was
hair follicle damage and reduction of hair follicles histologically. A
longer follow-up period is required to elucidate the long-term ef-
fects on hair follicles.
Analysis of histological changes has further demonstrated that
microwave energy reaches the interface of the deep dermis and
subcutis. This results in destruction of the eccrine and apocrine
glands without seriously damaging the surrounding tissue. Some
clinical adverse events were compatible with histological ﬁndings
(Table 3), such as numbness and nerve injury, hypotrichosis, and
damage to hair follicles. Nerve injury was not found in some pa-
tients who experienced numbness, because the nerve could be
destructed or not present in the histological section. No patient had
clinically evident bruising at the 30-day follow-up visit, and thus
microscopic hemorrhage may result from skin biopsy per se.
Immunohistochemistry staining with CAM5.2 highlighted apocrineFigure 6 Postoperative median pain score using energy level 3 (red) and energyglands, providing a convenient way to evaluate the extent of sweat
glands destruction.
There are many treatments for axillary osmidrosis reported in
the literature, such as conservative treatments (topical agents,
botulinum toxin) and surgical treatments (subcutaneous shaving,
tumescent liposuction with or without curettage, thoracic sym-
pathectomy).1e3,9e14Most of them are targeted at the axillary sweat
glands. Surgical treatments have been proven to be deﬁnite and
effective treatments while the effect of botulinum toxinwas shown
to be temporary and insigniﬁcant.9 Subcutaneous shaving is the
procedure most commonly performed in our institution.10
Although different techniques have been proposed to reduce
complications, such as hematoma, epidermal necrosis, and scar-
ring, these complications are not uncommon.3,9e13 Furthermore,
this technique was associated with more postoperative pain, longer
operation time, shoulder range of motion limitation, and approxi-
mately 10-day postoperative downtime, which may interfere with
daily activities.10 By contrast, we have shown that microwave-
based device treatment has less postoperative pain, shorter re-
covery time, and minimal interference with daily activities. Patient
satisfaction was also high (85.7%) and comparable with a previous
study using subcutaneous shaving with a suction-assisted cartilage
shaver.11
In conclusion, the miraDry system is a novel microwave energy
device that can be used to treat not only axillary hyperhidrosis but
also osmidrosis by heating the lower dermis and superﬁcial sub-
cutis, where the eccrine and apocrine glands are located. Patient
satisfactionwith the procedure is high, and adverse events are self-
limited and well tolerated. This system provides a noninvasive and
deﬁnite alternative therapeutic modality for patients with this
common and distressing problem.
Nonetheless, the recurrence of odor and its relationshipwith the
number of residual viable apocrine glands remains unknown, since
no deﬁnite evidence of correlation was found in our study. Further
studies to establish long-term efﬁcacy, long-term histological
changes, and recurrence rate are necessary.level 5 (blue). Note that the pain was greater and lasted longer using level 5.
Figure 7 Common adverse effects. (A) Mild swelling immediately after treatment (D0). (B) Bruise and some lumps could be seen on D2. (C) Bruise and lumps subsided partially with
some hyperpigmentation on D6. (D) All lumps and hyperpigmentation had resolved by the 90-day follow-up visit. Note the hypotrichosis.
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